Evidence map›Paper›PMID 37615030›Full record

ArticleNature machine intelligence2023

Prediction of mechanistic subtypes of Parkinson's using patient-derived stem cell models.

Karishma D'Sa, James R Evans, Gurvir S Virdi, Giulia Vecchi, Alexander Adam, Ottavia Bertolli, James Fleming, Hojong Chang, Craig Leighton, Mathew H Horrocks and 3 more

Open access · hybridAbstract read
In one paragraph

Article in Nature machine intelligence, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Neuroprotection in Parkinson Disease.Neurology and therapy · 2025
    Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 3 countries.

Karishma D'Sa *Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.
James R Evans *Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.
Gurvir S Virdi *Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.ORCID 0000-0002-8942-0903
Giulia VecchiFaculty, Marylebone, London, UK.
Alexander AdamFaculty, Marylebone, London, UK.
Ottavia BertolliFaculty, Marylebone, London, UK.
James FlemingThe Francis Crick Institute, King's Cross, London, UK.
Hojong ChangInstitute for IT Convergence, KAIST, Daejeon, Republic of Korea.ORCID 0000-0001-5385-4390
Craig LeightonEaStCHEM School of Chemistry, The University of Edinburgh, Edinburgh, UK.
Mathew H HorrocksEaStCHEM School of Chemistry, The University of Edinburgh, Edinburgh, UK.ORCID 0000-0001-5495-5492
Dilan AthaudaDepartment of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.
Minee L ChoiDepartment of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.ORCID 0000-0001-9414-8214
Sonia GandhiDepartment of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.ORCID 0000-0003-4395-2661
The Francis Crick Institute · GBFaculty (United Kingdom) · GBMRC Centre for Regenerative Medicine · GBKorea Advanced Institute of Science and Technology · KR

Funding

Medical Research Council MR/T008199/1
6 · The paper itself

Abstract

Parkinson's disease is a common, incurable neurodegenerative disorder that is clinically heterogeneous: it is likely that different cellular mechanisms drive the pathology in different individuals. So far it has not been possible to define the cellular mechanism underlying the neurodegenerative disease in life. We generated a machine learning-based model that can simultaneously predict the presence of disease and its primary mechanistic subtype in human neurons. We used stem cell technology to derive control or patient-derived neurons, and generated different disease subtypes through chemical induction or the presence of mutation. Multidimensional fluorescent labelling of organelles was performed in healthy control neurons and in four different disease subtypes, and both the quantitative single-cell fluorescence features and the images were used to independently train a series of classifiers to build deep neural networks. Quantitative cellular profile-based classifiers achieve an accuracy of 82%, whereas image-based deep neural networks predict control and four distinct disease subtypes with an accuracy of 95%. The machine learning-trained classifiers achieve their accuracy across all subtypes, using the organellar features of the mitochondria with the additional contribution of the lysosomes, confirming the biological importance of these pathways in Parkinson's. Altogether, we show that machine learning approaches applied to patient-derived cells are highly accurate at predicting disease subtypes, providing proof of concept that this approach may enable mechanistic stratification and precision medicine approaches in the future.

Indexed as

High-throughput screeningNeurodegeneration

Identifiers

PMID37615030
PMCPMC10442231
OpenAlexW4385741724

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.